Nanobiotechnology-based drug delivery in brain targeting

Area of Science:

• Neuroscience
• Biotechnology
• Materials Science

Background:

• The blood-brain barrier (BBB) significantly limits drug delivery to the central nervous system (CNS), hindering treatment for neurological disorders.
• Physiological factors like the reticuloendothelial system and protein opsonization further impede drug passage across the BBB.

Purpose of the Study:

• To review the role of nanotechnology, particularly nanoparticles, in overcoming BBB drug delivery challenges for CNS disorders.
• To explore recent advances in nanobiotechnology for improved drug targeting and therapeutic efficacy in the brain.

Main Methods:

• Review of current literature on nanoparticle-based drug delivery systems for the CNS.
• Analysis of various nanomaterials (liposomes, polymeric nanoparticles, nano-engineered devices) and their mechanisms for crossing the BBB.
• Examination of physiological approaches, including receptor-mediated transcytosis, to enhance brain drug delivery.

Main Results:

• Nanoparticles demonstrate significant advantages over conventional methods for BBB drug delivery due to their size and functionalization.
• Engineered nanoparticles and nano-engineered devices show potential for targeted drug delivery at the cellular level.
• Specific strategies, like using Angiopep peptide with LRP targeting, show promise for effective brain therapeutics.

Conclusions:

• Nanotechnology offers a transformative approach to enhance drug delivery across the BBB, improving safety and efficacy for CNS disorders.
• Nanoparticulate systems optimize drug pharmacokinetics, including biodistribution and controlled release, for site-specific targeting.
• Continued development of nanobiotechnology is crucial for overcoming drug delivery challenges in pharmaceutical biotechnology and brain therapeutics.